/CERO
CERO Stock - CERo Therapeutics Holdings, Inc.
Healthcare|BiotechnologyOTC
$0.10-8.65%
$0.01 (-8.65%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CERO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.09 – $0.10
TARGET (TP)$0.11
STOP LOSS$0.09
RISK/REWARD1:3.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.29
52W High$206.00
52W Low$0.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,163,379 | $-1,117,198 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-15,300,903 | $-2,932,985 | $-2,905,440 | $-332,030 |
| Net Income | $-7,732,000 | $-2,536 | $-667,736 | $-315,547 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-6.87 | $-2497.20 | $-19.73 | $-2.75 |
Company Overview
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$30
Average Target
↑ 31478.9% Upside
Now
$30
Low
$30
Average
$30
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 23rd 2025 | D. Boral Capital | Upgrade | Buy | $30 |
Earnings History & Surprises
CEROBeat Rate
67%
Last 3 quarters
Avg Surprise
-324.6%
EPS vs Estimate
Beats / Misses
2/1
Last 12 quarters
Latest EPS
$-9.10
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
+73.3%
$-1.59vs$-5.96
Q3 25
+50.3%
$-61.71vs$-124.26
Q4 25
-1097.4%
$-9.10vs$-0.76
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 19, 2025 | $-0.76 | $-9.10 | -1097.4% | ✗ MISS |
Q3 2025 | Aug 22, 2025 | $-124.26 | $-61.71 | +50.3% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-5.96 | $-1.59 | +73.3% | ✓ BEAT |
Q2 2025 | Apr 1, 2025 | — | $-1.75 | — | — |
Q4 2024 | Nov 19, 2024 | — | $-180.00 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.33 | — | — |
Q1 2024 | Mar 30, 2024 | — | $-31.28 | — | — |
Q4 2023 | Dec 30, 2023 | — | $-96.75 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-7.37 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-46.19 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-53.83 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-7.76 | — | — |
Q3 2022 | Sep 29, 2022 | — | $0.73 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.97 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-3.29 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-2.74 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Latest News
CERo Therapeutics Hldgs Q3 EPS $(9.10) Misses $(2.94) Estimate
📉 NegativeBenzinga•Nov 20, 2025, 12:36 AM
CERo Therapeutics Holdings Initiated Second Cohort Of Phase 1 CER-1236 Clinical Trial Focused On Patients With Acute Myeloid Leukemia
📈 PositiveBenzinga•Nov 5, 2025, 01:08 PM
CERo Therapeutics To Present Preclinical Data On Its Lead Compound, CER-1236, Showing CER-1236 Exhibits Sustained Effector Function, Robust Cytokine Responses, And Resistance To Exhaustion Compared To Standard CD3/CD28 Stimulation
📈 PositiveBenzinga•Nov 4, 2025, 02:11 PM
Maxim Group Downgrades CERo Therapeutics Hldgs to Hold
📉 NegativeBenzinga•Nov 3, 2025, 07:07 PM
CERo Therapeutics Shares To Continue To Trade Under Ticker CERO On OTC Markets
➖ NeutralBenzinga•Nov 3, 2025, 01:03 PM
CERo Therapeutics Holdings shares are trading lower after the company announced the determination of the Nasdaq Hearings Panel to deny the request to continue the listing of its shares on the Nasdaq.
📉 NegativeBenzinga•Oct 30, 2025, 01:10 PM
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
📈 PositiveBenzinga•Oct 30, 2025, 11:48 AM
Reported Earlier, CERo Therapeutics Receives Nasdaq Panel Determination To Delist Shares, Plans Appeal And Transition To OTC Markets
📉 NegativeBenzinga•Oct 30, 2025, 08:28 AM
CERo Therapeutics denied Nasdaq listing, seeks OTC markets
📉 NegativeSeeking Alpha•Oct 30, 2025, 05:04 AM
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
📈 PositiveBenzinga•Oct 22, 2025, 12:12 PM
CERo Therapeutics Authorizes Investigators Under Study Protocol To Administer Third Infusion Of CER-1236 To Patient Enrolled In First Cohort Of Ongoing Phase 1 Clinical Trial
➖ NeutralBenzinga•Oct 21, 2025, 12:19 PM
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
📈 PositiveBenzinga•Oct 13, 2025, 02:43 PM
'CERo Therapeutics CEO: We're "open" to takeover offers'- Axios
➖ NeutralBenzinga•Oct 10, 2025, 06:12 PM
Cero Therapeutics Has Received A Decision To Grant European Patent Number EP4376874 Titled "CHIMERIC TIM4 RECEPTORS AND USES THEREOF (FOR THE TREATMENT OF CANCER)"
📈 PositiveBenzinga•Sep 26, 2025, 07:59 PM
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 11:20 AM
CERo Therapeutics Doses Third Patient In Phase 1 AML Trial Of CER-1236
📈 PositiveBenzinga•Sep 22, 2025, 01:18 PM
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
📈 PositiveBenzinga•Sep 9, 2025, 12:41 PM
CERo Therapeutics Secures U.S. And Japanese Patents For CER-1236
📈 PositiveBenzinga•Sep 9, 2025, 12:18 PM
CERo Therapeutics Holdings shares are trading lower. The company announced it has administered a second dose in the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia.
📉 NegativeBenzinga•Sep 8, 2025, 04:09 PM
CERo Therapeutics Has Administered Second Dose To Second Patient In First Cohort Of Its Phase 1 Cer-1236 Clinical Trial For Acute Myeloid Leukemia
📈 PositiveBenzinga•Sep 8, 2025, 12:47 PM
Frequently Asked Questions about CERO
What is CERO's current stock price?
CERo Therapeutics Holdings, Inc. (CERO) is currently trading at $0.10 per share. The stock has moved -8.65% today.
What is the analyst price target for CERO?
No analyst price targets are currently available for this stock.
What sector is CERo Therapeutics Holdings, Inc. in?
CERo Therapeutics Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is CERO's market cap?
CERo Therapeutics Holdings, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does CERO pay dividends?
No, CERo Therapeutics Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCTXZ
BriaCell Therapeutics Corp. Warrant
$0.39
Mkt Cap: $0.0B
BIVI
BioVie Inc.
$1.41
Mkt Cap: $0.0B
ELAB
PMGC Holdings Inc.
$2.26
Mkt Cap: $0.0B
GLMD
Galmed Pharmaceuticals Ltd.
$0.85
Mkt Cap: $0.0B
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$0.79
Mkt Cap: $0.0B
MLEC
Moolec Science S.A.
$0.33
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
OCEA
Ocean Biomedical, Inc.
$0.00
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
XRTX
XORTX Therapeutics Inc.
$0.60
Mkt Cap: $0.0B
Explore stocks similar to CERO for comparison